Search | Clinical Trials Finder

Conditions: Influenza, SARS-CoV-2
Interventions: mRNA-1083 Composition 1 Dose A Lot A, mRNA-1083 Composition 1 Dose A Lot B, mRNA-1083 Composition 1 Dose B, mRNA-1083 Composition 1 Dose C, mRNA-1083 Composition 2 Dose A, mRNA-1083 Composition 2 Dose B, mRNA-1083 Composition 3 Dose A, mRNA-1083 Composition 3 Dose B, Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza Vaccine, Investigational COVID-19 Vaccine Lot A, Investigational COVID-19 Vaccine Lot B; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 1,320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 17
States / cities: Scottsdale, Arizona • San Diego, California • Stockbridge, Georgia + 13 more

Conditions: Healthy
Interventions: gp140, 50 mcg, gp140, 50 mcg + Adjuvant, gp140, 250 mcg, gp140, 250 mcg + Adjuvant, Placebo; Biological · Drug
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Tinnitus
Interventions: DMSO-based otic solution with betahistine, dexamethasone, and lidocaine, DMSO-based transdermal cream with levocarnitine and N-acetylcysteine; Drug
Lead sponsor: Leading Edge Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Ithaca, New York

Conditions: HIV Infections
Interventions: rgp120/HIV-1 SF-2; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 2
States / cities: Nashville, Tennessee • Seattle, Washington

Conditions: Influenza
Interventions: Inactivated Influenza H1N1 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 3 more

Conditions: Healthy
Interventions: Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp), MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.], MVA-BN-Filo 5*10^7 Inf. U., Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 525 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Covid19
Interventions: CVXGA1 low dose, CVXGA1 high dose; Biological
Lead sponsor: CyanVac LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Bardstown, Kentucky • Rochester, New York • Cincinnati, Ohio + 1 more

Conditions: SARS-CoV-2
Interventions: Not listed
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV Infections
Interventions: MRK Ad5 HIV-1 gag vaccine, Vaccine placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 27
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 19 more

Conditions: COVID-19 Infection, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Electronic Health Record Review; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: HIV Infections
Interventions: Ritonavir, gp160 Vaccine (Immuno-AG), Stavudine, Didanosine; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1999
U.S. locations: 1
States / cities: Stanford, California

Conditions: Genital Herpes
Interventions: mRNA-1608, BEXSERO; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 303 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 23
States / cities: Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 20 more

Conditions: Dengue Fever
Interventions: TAK-003, Placebo; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 923 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 14
States / cities: Huntsville, Alabama • Anaheim, California • Boise, Idaho + 11 more

Conditions: Parvovirus B19 Infection
Interventions: VAI-VP705 (parvovirus B-19 vaccine), Placebo, MF-59; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Baltimore, Maryland • Cincinnati, Ohio • Houston, Texas

Conditions: Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus
Interventions: Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 25 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Conditions: AIDS Vaccines, HIV Infections, HIV-1
Interventions: VRC-HIVADV027-00-VP, VRC-HIVADV038-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Relapsing Multiple Sclerosis (RMS)
Interventions: Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Phoenix, Arizona • Hollywood, Florida • Wellesley, Massachusetts + 4 more

Conditions: HIV Infections
Interventions: Clade B gag DNA/PLG and env DNA/PLG Microparticles, Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2007
U.S. locations: 4
States / cities: St Louis, Missouri • Providence, Rhode Island • Nashville, Tennessee + 1 more

Conditions: HIV Infections
Interventions: gp160 Vaccine (Immuno-AG), Hepatitis B Vaccine (Recombinant); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 2
States / cities: Baltimore, Maryland • St Louis, Missouri

Conditions: Chronic Lymphocytic Leukemia, COVID-19 Infection
Interventions: Biospecimen Collection, mRNA COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1; Procedure · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Healthy Adult Immune Responses to Vaccine
Interventions: VRC-EBOMAB092-00-AB (MAb114); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma
Interventions: COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1; Biological · Other
Lead sponsor: GeoVax, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 6
States / cities: Duarte, California • Baltimore, Maryland • Worcester, Massachusetts + 3 more

Conditions: HIV Infections
Interventions: ALVAC-HIV gp160MN (vCP125), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1995
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: APL 400-003; Biological
Lead sponsor: Apollon; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers

DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months

H1N1 Vaccine at Two Dose Levels in HIV Positive Adults

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents

Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study

Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients

Efficacy and Safety of COVID-19 Vaccine in Cancer Patients

A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells

A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue

B-19 Parvovirus Vaccine Study

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

Phase 1 Safety Study of Two Experimental HIV Vaccines

A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals

A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia

Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers

A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected Patients